Bristol-Myers To Market Two Cancer Drugs in Japan Next Year
This article was originally published in PharmAsia News
Executive Summary
Bristol-Myers Squibb says it plans to begin marketing a pair of cancer drugs in Japan next year. The U.S. company applied for market approval from Japan's Ministry of Health, Labor and Welfare for the two drugs and expects to begin marketing the first, Sprycel (sasatinib) for chronic myeloid leukemia early in 2009. Next, Bristol is looking to sell its Ixempra (ixabepilone) for treating breast cancer as early as the second half of 2009 or the first half of 2010. CEO Lamberto Andreotti says that with both drugs on the market, Bristol hopes to double its annual revenues in Japan over the next five years. (Click here for more - a subscription may be required
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.